Drug Profile
ATON 004
Alternative Names: ATON-004Latest Information Update: 18 Jul 2018
Price :
$50
*
At a glance
- Originator Aton Pharma
- Class Antidotes
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Poisoning
Most Recent Events
- 13 Jul 2018 Valeant Pharmaceuticals International is now called Bausch Health Companies
- 31 May 2010 Phase-II clinical trials in Poisoning in USA (unspecified route)